Home / Transcripts / Teva Pharmaceutical Industries Limited (TEVA) · November 5, 2025

Teva Pharmaceutical Industries Limited (TEVA) Earnings Call Transcript

November 5, 2025

New York Stock Exchange US Health Care Pharmaceuticals earnings 62 min

Earnings Call Speaker Segments

Chris Stevo executive
#1

Thanks, Alex. Hello and welcome, everyone, whether you're joining us this morning or this afternoon. Shortly, I'll turn things over to Richard Francis, my CEO. Prior to doing so, though, I have both the responsibility and the privilege of covering our forward-looking statements. During today's call, forward-looking statements will be part of what we discuss, and once this call concludes, we assume no responsibility to revise any of them. Should you want more detail on those forward-looking statements, you're welcome to review the applicable portions of our SEC filings on Forms 10-Q and 10-K. That said, here's Richard Francis.

Richard Francis executive
#2

Thank you, Chris, and greetings everyone, whether it's morning or afternoon where you are. We appreciate you being on today's call. Joining me for this session are Dr. Eric Hughes, who leads R&D and serves as Chief Medical Officer, along with Eli Kalif, Teva Pharmaceuticals' CFO. So let me begin, as is my habit, with our shift toward growth as a strategy. For the past 3 years, Teva has been guided by this approach, which rests on 4 pillars: executing with our growth engines — that means pushing AUSTEDO, UZEDY and AJOVY, our innovative portfolio; ramping up innovation, which Eric will cover, given the strong strides we're making throughout our innovative pipeline; maintaining a robust generics operation and the efforts we've made to bring stability to that side of the business; and then concentrating the business, and I'll update you on how far along we are in transforming Teva, our $700 million cost savings programs, plus news on TAPI. Let's turn now to the numbers themselves. I'm happy to report that this marks our 11th consecutive quarter of growth, with revenue rising 3% to $.5 billion, adjusted EBITDA climbing 6%, and non-GAAP EPS increasing 14%; all of these measured against Q3 2024. Free cash flow came in slightly above $0.5 billion. It's a real pleasure to share that our net debt to EBITDA has fallen below 3x, something that hasn't happened since 2016. Onto the following slide, which happens to be one of my favorites, I'll admit; here we see our 11th straight quarter of growth following a long stretch of declining sales; worth remembering that Q3 '24 made for a tough comparison, since we grew 15% then. So managing 3% growth against that baseline, I'd argue, speaks to what we've accomplished with our portfolio and to our teams. This keeps us on pace to hit the growth targets we laid out for 2027, namely mid-single-digit growth. So well done to everyone across the team who's delivered this across the last 11 quarters. Digging in a little further, here's what stands behind that $4.5 billion in revenue and the 3% growth; our innovative products led the way, and I'm delighted to note they now exceed $800 million for the quarter, with growth of 33% versus a year earlier. AUSTEDO posted an impressive 38% gain, hitting $618 million. UZEDY had a strong showing, rising 24% to $43 million, and AJOVY did well too, climbing 19% to $168 million. Global generics revenue rose 2%, while TAPI declined 4%, which mirrors some seasonal swings; so now I'll zoom in and explore each of these areas more closely, beginning with AUSTEDO. As you're aware, AUSTEDO was picked earlier this year by CMS for the 2027 price negotiation. And I'm happy to report that the deal we finalized aligns with what we told you to expect midterm for AUSTEDO when we initially shared those figures in May 2023. Because of that, we're able to affirm confidently our 2027 revenue goal of $2.5 billion along with our peak sales objective of more than $3 billion. Now, let's dig a little deeper into AUSTEDO for Q3. That marked yet another robust quarter for AUSTEDO, and the team keeps delivering outstanding results. U.S. sales hit $601 million during Q3 '25, which represents 38% growth year-over-year. That's also the very first occasion we've crossed the $600 million mark. So kudos to the team for their dedication in getting us here — it genuinely shows how well this group grasps the market. TRx rose 11%, and penetration of AUSTEDO XR keeps climbing. It bears repeating for everyone that AUSTEDO XR needs fewer prescriptions than the original AUSTEDO, which is precisely why examining milligrams dispensed matters just as much. And those, as you can see, climbed 25%. Now, looking at this slide, we've pointed out that as 2026 draws near, we have solid visibility into AUSTEDO's formulary positioning for 2026, and we keep striking the right balance between protecting value and preserving access. Given those impressive Q3 results, we're able to raise our revenue guidance for AUSTEDO to a range of $2.05 billion to $2.15 billion for the full year. Turning now to UZEDY, another thrilling piece of our innovative portfolio. UZEDY keeps delivering solid performance. Momentum is still robust as we keep serving mild-to-moderate patients along with those beyond who are on risperidone. Revenue climbed 24% year-over-year, while TRx jumped a hefty 119%. Worth pointing out that a onetime Medicaid gross to net adjustment partly weighed on revenue growth. That said, it has no bearing on our long-term LAI franchise projections, and we restate our peak sales goal of $1.5 billion to $2 billion for the franchise. This conviction stems from the data itself. UZEDY's NBRx sits well above its TRx. As you're aware, during Q3 we also secured an expanded indication for bipolar I disorder. To offer more direction on modeling UZEDY ahead, the Q4 implied guidance range of $55 million to $65 million gives you a cleaner run rate for projections moving forward, thanks to that gross to net adjustment from Q3. But let me use a couple of slides to share the enthusiasm we feel about our LAI — our long-acting franchise in schizophrenia. And what makes us believe that $1.5 billion and $2 billion figure is within reach? Well, it truly boils down to the excellent progress already achieved with UZEDY. You can see how much momentum this team has built, with TRx growth reaching 119%. UZEDY gives us a strong product profile, and we expect olanzapine to have a similarly compelling one. Even more important, though, are the capabilities and expertise developed here: the same individuals sit across from major payers, from key physicians, from key nurse practitioners, from health care providers, from patient associations, and from those responsible for formulary committees. That leaves us in a very strong position. We also recognize and believe that a significant unmet need exists in olanzapine for long-acting treatment. Bring those 2 things together on this slide, and we can treat as much as 80% of schizophrenia patients with UZEDY and our long-acting olanzapine — mild to moderate cases with UZEDY, moderate to severe cases with long-acting olanzapine. One more point worth highlighting: sadly, 4.7 million people in the U.S. and Europe live with schizophrenia. So both brands face a significant opportunity. That is why our confidence in the $1.52 billion stays strong. Turning now to AJOVY. AJOVY, I truly love. In a market that remains highly competitive, it keeps growing strongly across every region; and here are some nice data points; among the top U.S. headache centers, we rank #1 in new prescriptions for preventative CGRP injectables, and across Europe and international, we rank #1 in preventative CGRP injectables in 30 countries. We therefore confirm guidance of $630 million to $640 million. Now, remaining on innovation.

Richard Francis executive
#3

I want to spend a moment on the innovative pipeline — I realize Eric is going to cover this with you afterward, but I'm really enthusiastic about it. Why is that? Since it's near term; these assets are late-stage. With olanzapine, I'll discuss the filing for that during this year. For DARI, the solid enrollment we're seeing to bring it to market in '27. Duvakitug, we're kicking off our Phase III trial. Emrusolmin, terrific recruitment there. Then I glance at the right-hand portion of the slide, and I notice the potential for peak sales, which exceeds $11 billion. And let me remind you, that figure applies only to the indications shown on this slide. We recognize that duvakitug and anti-IL-15 will each be developed for a number of different indications. That gives Teva some genuinely strong growth engines for the years ahead. Let me shift over to the generics side of things. Sales in our generics segment were up 2% compared with 2024, driven by new product launches as well as gains in biosimilars and in our OTC operations. As I mentioned a moment ago, we usually look at this business through a 2-year CAGR lens, purely because of how the timing of launches naturally plays out here. As for the geographies, we had an exceptionally strong quarter in the U.S. During the third quarter, there was a 7% increase. That came about through multiple product introductions and particularly robust results from biosimilars, along with certain timing effects related to our generic Revlimid—which, I want to point out, will not recur to the same extent in the fourth quarter. In Europe, we saw a 5% decline, mostly driven by challenging year-over-year comparisons stemming from a series of launches and tender victories that span 2-year periods. This amounts to a 1% CAGR over those 2 years. International markets grew 3%, which is 12% on a 2-year CAGR basis. At this point, though, I'd like to spend a moment on our biosimilars, since our biosimilars portfolio is heading into an exciting period. At present, we've got 10 in-line assets worldwide, and through 2027 there's room to bring 6 more to market. That keeps us squarely on course to tack on an additional $400 million by 2027, matching the forecast we shared at the beginning of this year. Keep in mind as well that right now our biosimilars growth is robust despite having no meaningful launches or revenue in Europe — the biggest region for biosimilars. Down the road, our European pipeline will begin turning into launches and revenue, and past 2027 biosimilars are set to grow into a bigger overall driver for Teva. Now moving on to the fourth pillar, focus our business; we made significant progress with the Teva transformation program, and this is something we started at the start of this year. And we made a commitment to realize 2/3 of the $700 million by the end of 2026. And I can tell you we're on track to do that. What lets me say that is the fact that we are set to achieve the targets we laid out for 2025, which positions us nicely going into next year. That said, I'll let Eli cover this in greater depth a little later in the presentation. Before passing things to Eric, though, I'd like to update everyone on where we stand against the 2027 objectives, which we are reaffirming as of today. So looking at revenue, now that the IRA negotiations have concluded, combined with the launches ahead of us and our generic business leveling out, we project finishing 2025 in a 3% to 4% growth range, in line with the mid-single-digit average growth we've discussed for '23 to '27. Turning to OP, thanks to the effort we've put into expanding our innovative portfolio — which, as a reminder, is up 33% — along with the strides we've made in organizational effectiveness, we remain on course for a 30% margin. For this year, we'll close out at roughly a 27% margin overall. And net debt-to-EBITDA has fallen under 3x, which I touched on earlier. As this year wraps up, we ought to be near 2.8x, squarely on track to reach 2x by 2027. With that, I'll turn things over to my colleague, Eric Hughes.

Eric Hughes executive
#4

Thank you, Richard. So, to build on what Richard mentioned, we've got a solid set of late-stage programs in our innovative medicines, and we're putting even more focus into getting these studies done on schedule and with efficiency. Starting with olanzapine LAI, we remain on course to file with the FDA later this quarter. For our DARI program, covering both adults and pediatric patients, we're aiming to complete enrollment by the close of this year. With our duvakitug program, done in collaboration with Sanofi, we've now launched Phase III trials in both ulcerative colitis and Crohn's disease. For emrusolmin, we've reached the 100 patients required for our futility analysis by the end of next year, and enrollment is continuing at a strong pace. Lastly, our anti-IL-15 program — a very promising one with several possible future indications — is where we expect to read out proof-of-concept results from our celiac and vitiligo studies during the first half of next year. So these are truly exciting late-stage programs. But before I dive into those with more specifics, I want to give a shout-out to the UZEDY team for bipolar I disorder. We secured an approval and a label expansion, and we're quite proud of that. The team took an innovative route, leveraging the well-known, well-characterized pharmacology of UZEDY along with our safety database, combined with efficacy through a modeling and simulation method, to broaden that label for patients who suffer from bipolar I disorder. So it's a great innovative approach, very efficient execution, and a wonderful opportunity for patients to receive treatment for their bipolar disease. Now, turning to olanzapine LAI: as we've noted, we actually presented the data — both safety and efficacy from the full Phase III program — at the 2025 Psych Congress Annual Meeting. It was very well received. Safety and efficacy came out exactly as we anticipated. And most importantly, there were zero cases of PDSS. That submission is planned for the latter part of this quarter. So we're on track, and it's an exciting opportunity for patients down the road. Moving to our dual action rescue inhaler program for asthma, our ICS/SABA Phase III program. This is the biggest study Teva has ever run. Currently, we're on track to complete enrollment of our adults and pediatric patients by the end of this year. And keep in mind, the real value here is that in our label, we expect to include pediatrics, which represents 25% of the market. On top of that, we'll have a dry powder inhaler — a simple device to use: just open, inhale and close. That makes things far more convenient for adults and especially for pediatric patients. So it's a great program, right on track. And as I said earlier, we're very excited to share that we've now kicked off both the ulcerative colitis and Crohn's disease Phase III programs alongside our partner, Sanofi, for our duvakitug program. So this is a program that's generating a lot of excitement, with a great deal of work contributed by numerous individuals. The study in ulcerative colitis goes by the name SUNSCAPE, while the Crohn's disease effort is known as STARSCAPE. What has us genuinely enthusiastic here is how the Phase III has been structured. There's an open label feeder arm built in, and because it's open label and participants are aware they'll receive treatment, enrollment should happen at a very rapid pace — yet that still allows us to reach our safety figures quite quickly in the maintenance portion. The randomization ratio favoring patients assigned to active treatment is a favorable one. A rerandomization design is in place, which is genuinely a more workable or advantageous approach when it comes to multiple doses, and it better mirrors how things are done in actual clinical practice. And last, though perhaps the most significant point of all, subcutaneous injections form the foundation of the whole program. That means a loading dose, an induction rate, and then maintenance across the entirety of the program. So this is a genuinely patient-friendly program, built to be executed at speed. I'd also note that we moved this MOA from Phase II into Phase III faster than anyone else did; so from here on it's purely a matter of execution, with an excellent program in place. So credit goes to the team. Now turning to emrusolmin. I always prefer to begin by noting that emrusolmin is enrolling a patient population facing a genuine unmet medical need. The condition is multiple system atrophy, and our differentiated molecule goes after the earliest stage of the alpha-synuclein aggregates. Our design is highly efficient. As you can see here, it's a 48-week design against placebo; and as I mentioned, enrollment is proceeding very well, and we already have the first 100 patients who will take part in the futility analysis at the end of next year. So we remain right on track, and things are moving fast. We take pride in the fact that this has been granted fast track designation, and the orphan designation is already secured as well. So there's more to come. And lastly, I'd like to briefly address the anti-IL-15 program. This is yet another excellent homegrown antibody and program originating from the Teva laboratories. At present, we have it in proof-of-concept studies for celiac disease and, importantly, for vitiligo as well, with data due to read out in the first half of next year; but the potential upside here spans multiple different indications. Keep in mind that IL-15 is a key cytokine in the activation and proliferation of NK cells and T cells, and it's thought to play a role in many different indications, which you can see here; so there's a great deal ahead for IL-15, and it's a very exciting program, which also received fast track designation. With that, I'll hand things over to my colleague, Eli Kalif.

Eliyahu Kalif executive
#5

Thank you, Eric, and good day to everyone, no matter what time it is where you're listening from. Let me start by offering a handful of important points that demonstrate just how steady our performance has been over the past several quarters, this one included. First off, our third-quarter numbers landed well ahead of merely adequate, driven yet again by the fast-growing lineup of new products we've been bringing to market. As Richard noted earlier, this represented our 11th consecutive quarter of top-line expansion. On top of that, we continue to strengthen our balance sheet — notably, we reduced net debt to below $15 billion while EBITDA rose, which brought our net debt-to-EBITDA ratio under 3x for the first time since the third quarter of 2016. Third, we've made substantial headway on our transformation initiatives—by the third quarter, we'd already realized about half of the $70 million in savings we set out to capture for 2025. We're still positioned to deliver net savings of roughly $700 million come 2027, and to hit our 30% operating margin goals. And last, the IRA negotiation result for AUSTEDO landed pretty much in line with what our model had projected, which strengthens our conviction that we'll reach $2.5 billion in revenue for 2027 and surpass $3 billion at peak for AUSTEDO. Let's now move to Slide 30, where we'll review our Q3 2025 financial results, starting with GAAP performance. Before we go further, note that any growth rates for revenue I discuss will be expressed in local currency unless stated differently. As was the case in the prior quarter, I will also reference some Q3 2024 figures that exclude anything contributed by the Japan business venture, which was divested on March 31, 2025, allowing for an apples-to-apples view of our financial performance. Revenue for Q3 reached about $4.5 billion, representing a 5% increase in U.S. dollars, or 3% in local currency. Driving this expansion were mainly the ongoing strong momentum behind our key innovative products — AUSTEDO, AJOVY, and UZEDY — as well as our U.S. generics offerings, biosimilars included. This was partly balanced out by weaker European generics and reduced income from divesting certain product rights compared with Q3 2024. On a GAAP basis, net income reached $433 million, with EPS at $0.37. Relative to the third quarter of 2024, currency fluctuations in the period—counting hedging impacts—added $106 million to revenue and $21 million to operating income. Turning now to our non-GAAP results: gross margin on that basis climbed 120 basis points versus a year earlier, landing at 55.3%. That improvement slightly exceeded our forecast, largely due to robust AUSTEDO expansion, which kept pushing our portfolio mix in a more favorable direction. Gross margin also got a boost, though a smaller one, from changed ordering patterns for the generic Revlimid in our U.S. generics business, which shifted some volume from the second quarter into the third quarter, plus favorable FX; this strong non-GAAP gross margin performance largely flowed through to non-GAAP operating margin, which rose roughly 70 basis points year-over-year to 28.9%; that was partly offset by higher planned OpEx investment and the impact of foreign exchange movements. To sum up, we closed out the quarter with non-GAAP EPS of $0.78, which is up $0.10, or 14%, compared to the same period last year. In the third quarter of 2025, total non-GAAP adjustments came to $478 million. Free cash flow for Q3 stood at $515 million, versus $922 million in Q3 2024. The main drivers of that decline were the timing of sales and collections, plus larger payments for legal settlements — something we had anticipated for this year and which is baked into our full-year free cash flow guidance. Turning to Slide 31. Through well-defined, targeted efforts, we're achieving meaningful progress in our Teva transformation programs, aimed at delivering sustainable margin gains while preserving our capacity to innovate and invest in long-term growth. Between 2025 and 2027, these programs should generate net savings of roughly $700 million, and about 2/3 of that amount is expected to be realized across 2025 and 2026. We're still very confident about hitting roughly $70 million of early savings in 2025, and by the end of Q3, half of that was already locked in — which really shows the momentum and execution behind it. Also worth noting: what we're doing here isn't just about trimming expenses. This transformation is central to Teva's journey toward becoming a modern, innovative biopharma company, and to steering resources into the areas that fuel growth and innovation. Add in the ongoing move of our portfolio toward innovative products with high growth and high margins, and those transformation efforts give us a clear, credible route to reaching our 30% operating margin goal by 2027, all while we continue putting money into the business. In connection with those initiatives, we've booked about $190 million in restructuring charges so far this year, and we anticipate a total cash outflow ranging from $70 million to $100 million during 2025. Both the expected savings and that cash outflow are already baked into the guidance we provided for 2025. Let's turn to the following slide now, where we'll cover an update on our strategic direction as well as where things stand and how the process is going for divesting TAPI. As we've told you all consistently and openly, we had been engaged in exclusive negotiations with one particular buyer regarding a TAPI sale. At this stage, we've decided against moving forward with that negotiation, because we were unable to arrive at terms consistent with Teva's long-term priorities and the interests of our shareholders. Although that effort didn’t end with a deal involving the first prospective purchaser, the way geopolitics and market circumstances have recently changed makes TAPI more appealing to parties who might want to buy it. Our position remains that TAPI carries significant worth, yet it falls outside the strategic focus of our shift toward growth priorities. A fresh divestiture effort is therefore being launched so we can examine other paths and achieve the greatest possible value creation. Additional information will be shared once a transaction occurs or another decision is reached. Turning next to Slide 33, where our 2025 non-GAAP guidance is presented. Looking at how we've done so far this year, it shows steady execution as we shift toward growth priorities — decent revenue gains, better margins, and cash generation, even with the hard comparisons from last year in our generics business. Given what we've delivered so far and with 2 months remaining, we're narrowing our 2025 outlook ranges for revenue, operating profit, adjusted EBITDA, and EPS. Let's begin with revenue. In line with what we told you last quarter, we're narrowing the full-year guidance range to between $16.8 billion and $17 billion. AUSTEDO is a standout in our pipeline, which continues to deliver strong results overall. This performance stems from solid demand and effective commercial execution. Given how well things have gone through the year so far, we're lifting our AUSTEDO guidance for the entire year by $50 million to $100 million. That puts the new range at $2.05 billion to $2.15 billion, representing 21% to 27% growth for the full year compared with last year. That said, we said last quarter that we expect worldwide generics revenue for the whole year to be flat on a local currency basis against 2024. The key factors are tough comparison deals from a year ago, the scheduling of certain launches, and softness in some markets. Now let's look at the remaining pieces of our financial guidance. Given how well we've done through the year to this point, we're now anticipating that our non-GAAP gross margin will come in at the top portion of the 53% to 54% range we previously provided.

Eliyahu Kalif executive
#6

What this suggests is that our Q4 margin will come in a bit below Q3's, largely driven by the usual generic Revlimid pattern, since we had moved most of our allocated volume by the close of Q3. Additionally, we are raising the bottom end of our non-GAAP guidance ranges for adjusted EBITDA, operating income and EPS, which aligns with the results we've posted so far this year, the continued momentum we anticipate from our innovation portfolio, and the cost savings generated by our transformation programs. Although we're still awaiting clarity on possible U.S. tariffs affecting pharmaceuticals, including how the ongoing 232 investigation turns out, the administration's comments to this point about potential exemptions for generics leave us encouraged. Tariffs that have already been confirmed and are currently in effect are, as before, baked into our 2025 guidance. Operating expenses should still land somewhere between 27% and 28% of revenue, in our view. As for free cash flow, our guidance range is unchanged at $1.6 billion to $1.9 billion. Let me restate that our full year guidance excludes the development milestone tied to the Phase III initiation of duvakitug UC and Crohn's indications; that said, to help with your modeling, we'd like to point out that how much this development milestone ends up contributing depends on when each of these 2 studies occurs. Given the current time lines, one development milestone should be earned in Q4 2025, and we expect the remainder in Q1 2026. For Q4 2025, we anticipate the first development milestone will add $250 million to revenue and roughly $200 million to EBITDA and free cash flow, net of certain transaction-related costs; that first development milestone should add about $0.14 to EPS. Let's move now to the next slide, which covers capital allocation. Our approach to capital allocation stays disciplined and centered on backing our pivot to growth strategy and reinforcing our balance sheet. As I noted at the start, we keep bringing our debt down while putting money into our go-to-market capabilities and innovation. Thanks to the steady gains in our free cash flow, we remain on track to hit our net debt-to-EBITDA target of 2x by 2027, and to hold at roughly that level afterward. Beyond our continued deleveraging and the progress we're making toward an investment-grade ratings, the discipline with which we execute also leaves us well positioned to thoughtfully assess further options for returning capital to our shareholders. Last, before I wrap up my review of our third quarter performance, I want to reaffirm our 2027 financial targets. The result of the IRA negotiation for AUSTEDO only strengthens our conviction and adds further clarity around delivering on these midterm goals; with that, I'll turn things back over to Richard for his closing remarks.

Richard Francis executive
#7

Thank you, Eli. Prior to wrapping up, I want to recap several of the growth drivers in place here at Teva. Since you — since we anticipate our innovative portfolio will keep fueling growth past 2027, it's clear we have considerable room to make that happen. Right now the foundation is AUSTEDO, and we restated our goal of hitting over $2.5 billion in '27 and surpassing $3 billion at peak, reflecting how our IRA negotiations with CMS concluded. Together with the innovative offerings UZEDY and AJOVY, we'll keep pushing our product mix and profitability forward. Beyond that, and to add to what Eric said, we're getting ready for thrilling innovative product launches over the coming few years, which ought to lay a foundation for growth in the years ahead. Turning to my last slide, a few closing reflections. During Q3 of '25, we kept delivering on our pivot to growth strategy, marking the 11th quarter in a row of growth and expanding our innovative franchise by 33%. We have a clear path towards our 30% operating margin and our other 2027 targets; we're moving our innovative pipeline ahead with near-term and long-term catalysts, and Teva's transformation remains well on track to deliver the $700 million in savings we committed to; with that, I'd like to open the floor for the Q&A. Thank you.

Chris Stevo executive
#8

Much appreciated, Richard. Alex, would you mind — pardon me, Alex, would you mind getting the question line started, and we'd ask that you keep it to a single question plus one short follow-up, and naturally, should time remain, we're glad to have you rejoin the line with further questions. Please proceed, Alex. Thanks.

Yuchen Ding analyst
#9

Perhaps a question regarding AUSTEDO and IRA. I appreciate the remark, and it's good to see you restating the long-term guidance for AUSTEDO. What more detail can you share about your own internal expectations as you entered those negotiations, and how does the agreed price compare with the current Medicare net price?

Richard Francis executive
#10

Dennis, I appreciate the question. As I said earlier on this call, it matched what we expected — consistent with our forecast from May 2023 when we established it. We had expected to be included on that list and to be in talks with CMS. That is precisely why we stay quite confident about reaching $2.5 billion in revenue. On the second part of what you asked, concerning net price, we won't address that, clearly, because of competitive considerations. Still, let me repeat that we think we can achieve $2.5 billion in revenue — first, since it aligns with our forecasted figure, and second, I want to remind everyone that tardive dyskinesia is still a condition that is heavily underdiagnosed and undertreated. Among patients dealing with this condition, 85% receive no therapy. That gives us a significant opportunity to assist those patients and to keep expanding AUSTEDO in '26 and beyond, which is why we restate the $3 billion — more than $3 billion in peak sales for AUSTEDO. Those are the points I bear in mind when you consider what lies ahead for AUSTEDO. Thank you.

David Amsellem analyst
#11

I also wanted to ask about AUSTEDO. Your competitor discussed what you might call dosing creep during its call. Basically, with a per-milligram pricing model, higher doses translate into greater revenue for each patient. What they claim is that health plans are starting to figure this out, and that patients could potentially shift over to the competitor's product. So I'd like to know whether you can share any color regarding how AUSTEDO XR is priced and whether that is creating any consequences when it comes to access for AUSTEDO XR. That's my first point. Second, how will that shape the way you approach commercial contracting for '26, and how far might you go in offering more price concessions simply to secure a stronger access position relative to your competitor?

Richard Francis executive
#12

Thank you, David. I appreciate the question. What the competitors are saying isn't something I'll address. My focus is on what we're doing at Teva. Let me point out that AUSTEDO's growth has far more to do with serving this underserved market, as I've mentioned before, and with our team's capacity to execute consistently. I'd also remind everyone that when this journey began back in 2023, the forecast for AUSTEDO's peak sales was $1.4 billion. As you can see, this year we will go past $2 billion. Credit for that goes to what we've accomplished as a company and the capability we've developed. As for milligrams per dose, we have been extremely clear regarding the advantages patients get from taking AUSTEDO XR and how that assists them with adherence and compliance. This also aligns closely with what was included in our Phase III trial, which gave physicians the flexibility to reach the optimal dose for their patients. So what we observe is simply a natural progression as patients move from BID to AUSTEDO XR, with physicians enjoying that flexibility to get patients onto the correct dose. The last portion of your question, I believe, concerned access. In my presentation I pointed out that we always think carefully about managing access alongside value. With AUSTEDO we have kept doing that. Incidentally, we've done so quite successfully with our other brands, UZEDY and AJOVY. I believe our capability in that area is genuinely strong. Still, let me return to what fuels our confidence in AUSTEDO, which comes down to 2 things. One is the capability this team inside Teva possesses, and the other is the underserved market, where 85% of patients who could be on therapy are not on therapy. Those are the 2 things we concentrate on. Thank you for the question, David.

Jason Gerberry analyst
#13

My question concerns operating expenses for 2026. Consensus appears to have R&D plus SG&A combined at roughly $4.8 billion, which is essentially level compared with the prior year. Does that match your view of how the cost savings will move through the P&L as you manage the Revlimid loss of exclusivity? Then a quick follow-up: could you say anything about whether AUSTEDO XR ended up inside or outside the IRA? I'm aware there was litigation related to that, so I'm curious whether you can provide any clarity there.

Richard Francis executive
#14

I'll direct the OpEx question — thank you, Jason, for asking it. I'll pass that over to Eli to respond.

Eliyahu Kalif executive
#15

Appreciate that, Jason. Regarding how OpEx for '26 will shape up, we've consistently said that going forward, some portion of the $700 million in savings will land in COGS, though the bulk of it goes to OpEx. And to the extent we continue expanding and can keep driving profit, you'll find us sitting between 27% and 28%. That won't be changing. Even so, we'll be in a position to grow both our OP and our EBITDA. So here's how to frame it: roughly 2/3 of that $700 million in savings should be delivered before '26 wraps up, and we'll begin seeing a piece of it hit COGS as well. The biggest piece tied to COGS, though, actually shows up in '27. That said, I can share that the lion's share of the savings should be delivered before '26 ends, with most of that tied to OpEx. So treat that 27% to 28% as a run rate.

Richard Francis executive
#16

Appreciate that, Eli. Now, on your second question about whether AUSTEDO XR falls within the IRA negotiations — yes, it does.

Chris Schott analyst
#17

Let's change topics for a moment. Could you discuss the dynamics of your EU generics? I realize you're up against some harder comparisons this year. But I wanted to know whether anything has shifted in those underlying markets that we ought to consider when thinking about future growth. And a quick follow-up. I'm aware of the TAPI process. Could you give a bit more detail on the reasoning behind restarting that process rather than simply holding onto the asset? Perhaps say a few words about the overall level of interest in these API assets in the current market.

Richard Francis executive
#18

Thanks, Chris. I appreciate the questions; so let's turn to the EU Generics business. If I take you back to when we first began discussing Teva and our generics business in '23, I recall telling everyone that this is a market leader of scale in Europe. Therefore, the capacity to expand this business, we ought to view it as growing at roughly a 2% CAGR rate simply due to its scale and size; clearly, I was shown to be incorrect across the last 2 years since the business expanded beyond that. But a few factors caused that. First, we had additional launches during those years, and we also had rivals finding it hard to supply, and thanks to our manufacturing capability, we were able to fill the gap. So those 2 things occurred. And I believe what you're observing this quarter compared with the prior year is a somewhat similar pattern. What we have is more launches than we had in 2023 — sorry, in Q3 2024. We additionally had some tender wins, which cover 2-year tender periods; and we also had supply problems at competitors. Those no longer applied. So that's my way of thinking about it; and that's the reason I return to considering our generics business on a CAGR — 2-year CAGR, since if you consider a 2-year CAGR, these fluctuations even out, and that's our approach. And as we've talked, I constantly remind people that we view our generics business in the future within that 2% CAGR period, first, purely because of the scale we possess. Having said that, one point I do want to stress is our biosimilar business, while gaining traction in the U.S., we will begin now to launch and we have launched certain products and biosimilars in the EU, and that will begin to build momentum, especially after 2027, but we have a solid pipeline coming through in Europe. And we recognize that's a mature biosimilar market; and so those are things that will start to perhaps contribute to that growth in Europe going forward. But I hope that addresses your question. As for TAPI, I'll hand that question to Eli to explain why restart it and not retain it. Eli, the floor is yours.

Eliyahu Kalif executive
#19

Yes. Chris, thank you for asking. So, throughout the entire process, we were extremely open, and like we said, we ultimately chose not to move ahead with the exclusive talks we were having with one particular buyer. The reason is that we view TAPI as strategic for Teva going forward, in terms of our capacity to continue sourcing API when it is in fact operating as a stand-alone. You have to keep in mind, this isn't simply a business sitting on the shelf that you sell off and then move on; for us, this matters strategically going forward, and so does our capacity to ensure we deliver added value in both the near term and the long term to our future progress and growth. That's incredibly important. It emerged that particular elements of the discussion did not unfold in line with the terms by which we believe the deal ought to proceed. And so, we reached that decision; and beyond that, we must keep in mind that market conditions have now shifted. Since we kicked off this sales process. Recent geopolitical developments, as I noted, along with certain trade policies, underscore some ongoing appeal for TAPI regarding the landscape. Consequently, we chose to launch a revised strategic review and to review the sales process. And as I said, we'll keep everyone informed and offer further updates while awaiting the transaction or any other determination concerning this process.

Chris Stevo executive
#20

I might just jump in here, so that Eli isn't misinterpreted. What he's getting at when he calls it strategic is this: they rank among the biggest suppliers of API to us, and we have to make sure whatever agreement we sign carries appropriate terms — not only benefiting the buyer, but also benefiting Teva down the road, for both our marketed products and our pipeline.

Ashwani Verma analyst
#21

Nice job on the solid results. Perhaps just briefly regarding 2026 revenue and EBITDA, I was hoping to grasp whether you can keep producing expansion across both of those measures as part of your longer-term objectives. Revlimid is going away, yet you've laid out fairly significant cost reductions and also spoke positively regarding the AUSTEDO formulary; and then just one quick follow-up. So the 3Q AUSTEDO appears quite robust. Is that mostly ordinary underlying demand? Or does some sort of one-time boost exist within it? Usually, you get a fairly solid 4Q, yet given this reaffirmed guidance, it appears to be pointing toward a lower quarter in 4Q.

Richard Francis executive
#22

Ash, I appreciate your question. So beginning with the EBITDA, only to remind you a bit, and Eli, I believe, brought this up during his comments, the EBITDA is propelled by a few factors next year; and I believe grasping that matters. First, our innovative portfolio carries genuine momentum. Like I mentioned, it rose 33% in Q3. And these products are each expanding. Thus we keep witnessing excellent growth rates across them. And incidentally, we've discussed this previously. These carry very high gross margins. So that genuinely assists in shaping the EBITDA. So that's the first. And then regarding the — one of the slides that both Eli and I presented concerns Teva's transformation along with organizational effectiveness. We remain on track to accomplish precisely what we intended in '25, and that signifies our guidance toward 2/3 of the $700 million net savings for 2026, which we feel extremely confident about. So simply combining those 2 items genuinely provides us confidence regarding our EBITDA. Yet I'd likely seize this moment to discuss, well, we have certain other matters concerning our generics business where we've now forfeited generic Revlimid. There are 3 elements that assist us in propelling our generics business ahead, namely our generics, our complex and our OTC; and like we've stated previously, we possess the capacity to offset that generic Revlimid by the close of 2027 since we have those 3 distinct growth engines and the scale we hold across those 3 distinct businesses. So I believe that addresses that portion of the question; concerning the one about AUSTEDO, and I think you mentioned the robust Q3 and how that affects Q4? And was anything behind it? I think there are simply a few dynamics there. To begin, AUSTEDO's fundamentals are genuinely robust. It's truly crucial to grasp; so as you observe concerning our TRx, our milligrams, our growth rates, I think the team has kept executing at an elevated level consistently. And I think we've witnessed that quarter upon quarter upon quarter. There's a point I want to bring up, and I believe it came up during our previous call as well: during Q3 2024 and Q2 2024, we saw some channel stocking related to AUSTEDO XR, and that made for a somewhat different comparison, plus we had some modest gross-to-net adjustments on AUSTEDO that worked in our favor in Q3 of this year. If you strip those out, though, the trajectory for AUSTEDO really doesn't shift much. My habit is to view AUSTEDO across a yearly span, over multiple quarters, since I believe we've stayed consistent when it comes to reaching our numbers and our targets, and we're quite precise on that front. That's my frame of reference, so I'm not expecting anything particularly major in quarter 4. The channel is the one piece we always handle as best we can, yet it isn't entirely within our hands. We've stayed very disciplined about keeping the channel stocked correctly, but clearly that's a factor we can't fully control, though we've demonstrated solid discipline on it. I hope that addresses your questions, Ash, and thank you for asking them.

Leszek Sulewski analyst
#23

We noticed the FDA put forward new guidance regarding biosimilars, aiming to cut down on comparative efficacy trials and possibly accelerate how quickly approvals come through. So I've got 3 questions about that for you. First, what effect will this revised guidance have on your biosimilar plans for the long term? Second, looking at it from the other direction, could you envision a situation with more competition coming in, where eventually biosimilar price erosion patterns end up looking like what we see with traditional generics? Third, what additional investments do you believe are required to sharpen your competitive advantage? And I suppose, in the end, can you picture a situation in which the U.S. gets to a stage where the BLA process and patient access turn out to be equally advantageous compared with the EU?

Richard Francis executive
#24

Okay. Yes, that question had a lot of dimensions to it. So I appreciate that, Les. I believe I'll kick things off, though I'll also bring in my colleague, Eric, who clearly is quite close to this given the pipeline we've got. So to begin with, we feel good about the FDA and that move to eliminate Phase III studies. In my view, that's the correct action to take. I believe it's helpful. And it rests on data. We now possess a considerable volume of data in the development of these biosimilars across a great many, many products as an industry, and I think this is the correct action to take. Does our strategy shift because of it? Not in the slightest. I think it strengthens how sound the strategy is that we laid out for biosimilars in 2023. And to remind you what that strategy consisted of, our approach was to hold the largest — one of the largest portfolios of biosimilars moving forward, and we're going to achieve that via partnerships. We pursue it through partnerships since that let us have the largest portfolio since that let us allocate capital efficiently. We also believed back then that uncertainty would exist regarding what future regulation would look like; and so we had no desire to be initiating and allocating capital toward things that might not be required anymore. One illustration is kicking off Phase IIIs, which are — they're not required anymore moving forward. So I think we kind of thought about where the puck was headed. We built a strategy aimed at where the puck was headed, and I'm happy to say I think we've been shown to be correct about that. But in the end, our strategy centers on having a large portfolio. As I've just pointed out, we have 10 in the market. We have 6 we're going to launch by '27, and then we're going to have more moving forward. When it comes to price erosion, I think a solid comparison is to look at Europe. And Europe is a highly mature biosimilar market and, one, I know especially well. And what you observe there is good penetration. You observe that there is some price erosion, but it reaches a steady state at a certain time, which still permits a high level of profitability within this category. Another thing I want to point out about that market — since you brought up whether the U.S. might follow suit — is that you're seeing more of these molecules and biologics reaching patients, since they cost less and get used sooner when treating these conditions. That means volume goes up, which clearly offsets part of the price decline. Those are simply a few of the forces at play. And my view is that the U.S. will eventually catch up. That said, with a wide portfolio and additional launches underway in Europe, the timing isn't something we're strictly dependent on, given our scale and size. Eric, perhaps you could add some more specifics on your perspective here.

Eric Hughes executive
#25

Absolutely, I can add a handful of points that back up what you've just mentioned. We collaborate tightly with the FDA and communicate often regarding a fairly extensive biosimilars portfolio; we genuinely expected that they would drop the Phase III requirement for the majority of programs, and we're on board with that call. When it comes to biosimilars, the technical assessment has truly shown itself to be the single most critical element, and that's an area where we excel. On top of that, this will bring down the expense of producing and getting biosimilars approved. It aligns seamlessly with and enables the pivot to growth strategy we assembled previously, and honestly, it validates plenty of the sound choices we've made through the years concerning how we'd handle biosimilars at Teva. So we welcomed that decision. We had been anticipating it, and it truly slots right into the plan.

Richard Francis executive
#26

Appreciate that, Eric. There's one more point I want to tack on — clearly I overlooked mentioning it — dropping the Phase III requirement brings the expense down quite a bit. That said, I'd also stress that the outlay involved in bringing a biosimilar to market remains substantial, far greater than what you'd see with any standard generic or any complicated generic, for that matter. So my view is that neither the capital commitment nor the expense tied to it simply vanishes. Consequently, I still believe the count of players entering this space is going to stay limited for that reason. And what matters most isn't merely whether you can create and produce the product — it's whether you possess a go-to-market operation that's efficient. What we're beginning to demonstrate in the U.S., and what we'll demonstrate in Europe, is that we have exactly that. That front-end piece is crucial when it comes to sustaining growth as well as profitability across your biosimilar portfolio. So thank you for raising that, Les.

Umer Raffat analyst
#27

You mentioned that the CMS agreement matches what your models predicted. Can we reasonably figure that it lands somewhere around 50%, in that vicinity? Then second, when it comes to reaching $2.5 billion in sales by 2027, does that figure depend on assuming you'll move more volume thanks to this IRA reduction relative to Ingrezza, or is that not part of it? And last, clearly olanzapine seems to be dragging on longer than any of us expected. That said, could a commissioner voucher possibly speed things up at this stage? Or is that something we shouldn't even consider?

Richard Francis executive
#28

Umer, I appreciate those questions. Regarding CMS, it matched the expectations we laid out back in 2023. You put a number out there, and I won't address it, since I believe that was perhaps an attempt to coax a figure out of me, and that's not something I'll do. All I'll say is that it's in line, which is exactly why we stay highly confident in our $2.5 billion for '27. And let me remind everyone: peak sales beyond $3 billion. You brought up whether we anticipate volume growth here. This isn't something we've — without diving into the specifics of how we forecast, we return to the idea of bringing in more patients, helping patients stay more adherent and compliant, and all those basic elements. What I think you've hit on, though, is something we'll grasp better in January, once the initial group of drugs that were negotiated, along with CMS, begin to emerge and unfold. We'll observe whatever dynamics emerge there, and we'll apply that to refine our modeling down the road; and I hope you, like others, would agree that we're extremely careful about how we model and forecast. At least across recent years, I believe we've been fairly precise in what has been a rather dynamic setting. Turning now to olanzapine, I'll pass it to Eric to address whether a Commissioner's voucher might be obtainable.

Eric Hughes executive
#29

Absolutely, and thanks for asking, Umer. To begin with, the olanzapine LAI submission is proceeding exactly as we intended for this quarter. As for the Commissioner voucher question, that is something we at Teva have been examining. A real strength of Teva is our biosimilars, an entire portfolio of generics, plus innovative medicines. That means the possibilities for obtaining a Commissioner voucher are wide-ranging. So we are currently evaluating that and trying to determine which program would be the most optimal — best timed and most valuable — for pursuing one of those, though there will be more updates about it down the road.

Richard Francis executive
#30

Appreciate that, Eric.

Matt Dellatorre analyst
#31

Nice work this quarter, and good news on the AUSTEDO deal. To start with duvakitug — since the Phase III IBD trials are now underway, what's your view on how long enrollment will take and when we might see data? Also, any update you can give on growing the indications past IBD? For example, might we hear about proof-of-concept trials in the near future? Then, as a follow-up regarding capital allocation, what would you call the main priorities for 2026? And when we consider the free cash flow inflection, what should we be watching most closely to hit that full year '27 guidance?

Richard Francis executive
#32

Matt, I appreciate those questions. For the first one, on the Phase III and the possible Phase IIs, I'll pass it directly to Eric.

Eric Hughes executive
#33

Absolutely, and I appreciate you asking about that, because this design we've developed alongside Sanofi is honestly among the things that fires me up the most; at this point it's purely about how well we carry it out. Like I mentioned before, when you look at this mechanism of action, the jump from Phase II to Phase III happened faster than for any other program around, and that's something we take real pride in. So it really demonstrates what we can deliver when we work together in this partnership. The way the trial is structured is specifically intended to guarantee we bring in as many patients as possible through the feeder arm, which then feeds into our maintenance portion while also boosting the safety data we gather across the program. It's an extremely user-friendly, patient-focused setup when you consider the subcutaneous dosing and the re-randomization; all of those elements combine to make it a great fit for patients. On top of that, we're investing heavily in how we actually run the program, particularly around logistics and the vendors we've brought on board. So the collaboration with Sanofi has been truly excellent. I believe we're carrying forward a great deal of momentum and positive results from a Phase II effort that likely posted the strongest efficacy figures and dataset we've generated, and those are encouraging signs as we kick off a Phase III program. So as far as execution goes, that's where our attention is going to be from here. And I'd say we're positioned quite strongly to be in the race, maybe not right in the thick of it yet, but ideally we'll be right up near the front before long; so things are lined up nicely. Turning to what you asked about additional indications, it's wonderful to witness the enthusiasm surrounding this mechanism of action. What stands out is that it has the potential to affect so many distinct cytokine signaling pathways across a range of indications. You're already seeing numerous Phase II trials getting underway. Together with Sanofi we have a strategy in place, and once those studies kick off we'll share that with you; for the time being, though, we're keeping that information guarded. That said, along with the buzz about potential future combinations, it's something we've been giving serious thought to. But at this moment, what matters most as we open this conversation is carrying out the trial, getting patients enrolled, and proving the value in ulcerative colitis and Crohn's disease right now.

Richard Francis executive
#34

Thanks, Eric. Turning to the following 2 questions, which concern how we deploy capital and the turning point in free cash flow, I'll pass those along to Eli. But first, I want to say that I appreciate you calling attention to that inflection in free cash flow, since it's a topic we've begun discussing and one that others are beginning to notice as the business expands, as the innovative grows, as debt comes down, and as EBITDA rises — all of which, in the end, shifts where we stand on free cash flow. So thank you, Matt, for bringing that up and for recognizing it. That said, I'll turn things over to Eli, who can address how we'll approach capital allocation moving forward.

Eliyahu Kalif executive
#35

Yes. Matt, thanks for asking that. Let me begin with free cash flow. You brought up the way we ought to view that pattern we discussed past '27. Three primary forces are at play here. The first one is mix, correct? When you examine the top line, the way we're advancing on it, and the way it will pass through and turn profit into free cash flow given the innovative portfolio, I'd say, that we hold, and we continue putting money into our growth driver. The $700 million in savings will in fact let us achieve more efficient COGS alongside high gross margin, I'd add, so as to optimize our OpEx. Those 2 pieces are already underway. Two more exist that we must keep in mind. Number one, we settled our debt this quarter. Between now and October 26, roughly 13 months, no maturities fall due, there's $1.8 billion in October, plus a $2.8 billion in March, May in '27, early '27. Consider $4.5 billion, $4.6 billion at our present weighted cost of capital on outstanding debt of 4.8%, and that gives you $200 million to $250 million we will remove from a run rate, both from financial expenses ahead and pure free cash flow impact. And on top of that, our headway on working capital — you can genuinely see us operating below 4% starting from '27 onward on our revenue. All of this truly lets us convert high free cash flow. Regarding capital allocation for next year, we're in fact examining more, I'd say, capacity to compete on particular opportunities tied to business development that fit strategically with our portfolio and to ensure we can deliver value to our shareholders. And as we proceed to build synergetic activities around that piece, we'll continue looking at, naturally, bringing our debt down. And as we proceed, we might additionally examine some — certain other elements tied to capital and shareholder returns; and we will, certainly, during '26, and we hope also on our next earnings calls, offer some further colors regarding that sort of capital returns to shareholders.

Richard Francis executive
#36

Thanks, Eli. Thanks, Matt, thanks for your question.

Richard Francis executive
#37

Thanks to each of you for joining this call. Your interest in Teva is genuinely valued, and we're eager to share our full year results with you early next year. That's all from us — thank you.

Operator operator
#38

Thank you all for joining today's call. You may now disconnect your lines.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Teva Pharmaceutical Industries Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Teva Pharmaceutical Industries Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.